Form 4 Filing for Telomir Pharmaceuticals, Inc.

Matthew Pratt Whalen, a director at Telomir Pharmaceuticals, Inc., acquired 50,000 Non-Qualified Stock Options on April 16, 2026. These options, granted under the Issuer's 2023 Omnibus Incentive Plan, have an exercise price equal to the closing price of the Issuer's common stock on the grant date and immediately vested upon issuance. The options are exercisable for 10 years, expiring on April 16, 2036. The exercise price was reported as $1.34 per share, with a total of 50,000 shares of Common Stock underlying these options. Following this transaction, Mr. Whalen holds 50,000 shares of Common Stock.